Buscar

Barra de búsqueda
01/02/2025 A cross-sectional analysis from a real-world cohort of patients with microsatellite instability colorectal cancer (MSI-CRC) with metastatic disease from the Spanish RETUD registry.
Castro, CG, López, S, Garcia-Alfonso, P, Martinez, CF, González, BD, Ortiz, MJ, Paez, D, Lopez, CM, La Casta, A, Sosa, MM, Valera, JS, Ghanem, I, Vidal-Tocino, R, Santos, C, Garcia-Benito, C, Jimenez, E, Guillot, M, Verdaguer, H, Montes, AFF. A cross-sectional analysis from a real-world cohort of patients with microsatellite instability colorectal cancer (MSI-CRC) with metastatic disease from the Spanish RETUD registry.. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(4_SUPPL)DOI:10.1200/JCO.2025.43.4_suppl.178. PMID:. IF:41.900(Q1/1D).
01/02/2025 Plasma shallow whole-genome sequencing profiling in patients with RASWT metastatic colorectal cancer (mCRC) undergoing first-line anti-EGFR therapy.
Martelli, V, Barrull, JV, Fernandez-Rodríguez, C, Gibert, J, Moreno, A, Louhamane, A, Linares-Aceituno, J, Garcia-Alfonso, P, Paez, D, Alonso, V, Espana, MAG, Santos, C, Duran, G, Elez, E, Paricio, BB, Tabernero, J, Salazar, R, Aranda, E, Toledo, RA, Montagut, CO. Plasma shallow whole-genome sequencing profiling in patients with RASWT metastatic colorectal cancer (mCRC) undergoing first-line anti-EGFR therapy.. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(4_SUPPL)DOI:10.1200/JCO.2025.43.4_suppl.214. PMID:. IF:41.900(Q1/1D).
01/02/2025 A cross-sectional analysis from a real-world cohort of patients with microsatellite instability colorectal cancer (MSI-CRC) with localized disease from the Spanish RETUD registry.
Montes, AFF, Lopez, CM, Lopez, S, Martinez, CF, Paez, D, Gonzalez, BD, Espana, MAG, Garcia-Benito, C, Vidal-Tocino, R, Sosa, MM, Valera, JS, Garcia-Alfonso, P, Ghanem, I, La Casta, A, Gallego, J, Verdaguer, H, Santos, C, Jimenez, E, Gravalos, C. A cross-sectional analysis from a real-world cohort of patients with microsatellite instability colorectal cancer (MSI-CRC) with localized disease from the Spanish RETUD registry.. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(4_SUPPL)DOI:10.1200/JCO.2025.43.4_suppl.173. PMID:. IF:41.900(Q1/1D).
01/02/2025 Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research Recommendations in Women with Breast Cancer
Olmos, VP, Pollán, M, de Larrea-Baz, NF, Fernández-Morata, J, Ruiz-Moreno, E, García-Pérez, J, Castelló, A, Sierra, MA, Lucas, P, Alonso-Ledesma, I, Stradella, A, Cantos, B, Cajal, TRY, Santisteban, M, Seguí, MA, Bertrán, AS, Granja, M, Camps-Herrero, J, Recalde, S, Mendez, M, Verges, NC, Pérez-Gómez, B, Pastor-Barriuso, R, Lope, V. Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research Recommendations in Women with Breast Cancer. Cancers. 2025; 17(4)DOI:10.3390/cancers17040708. PMID:40002301. IF:4.400(Q2/3D).
27/01/2025 Therapeutic alliance in a stepped digital psychosocial intervention for breast cancer patients: findings from a multicentre randomised controlled trial
Flix-Valle, A, Medina, JC, Souto-Sampera, A, Arizu-Onassis, A, Juan-Linares, E, Serra-Blasco, M, Ciria-Suárez, L, Feixas, G, Ochoa-Arnedo, C. Therapeutic alliance in a stepped digital psychosocial intervention for breast cancer patients: findings from a multicentre randomised controlled trial. BJPsych Open. 2025; 11(1)DOI:10.1192/bjo.2024.844. PMID:39865983. IF:3.500(Q1/3D).
20/01/2025 Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS)
Martin-Broto, J, Diaz-Beveridge, R, Moura, D, Ramos, R, Martinez-Trufero, J, Carrasco, I, Sebio, A, Gonzalez-Billalabeitia, E, Gutierrez, A, Fernandez-Jara, J, Hernandez-Vargas, L, Cruz, J, Valverde, C, Hindi, N. Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS). JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(3)DOI:10.1200/JCO.24.00358. PMID:39356980. IF:41.900(Q1/1D).